Pwrm For $0.04 A Share! : Pwrm, Xprt, & Ipci

PWRM is now available for $0.04 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.
By: crwepicks
 
June 28, 2010 - PRLog -- POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

Last: $0.40

PWRM is now available for $0.04 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:

Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below:

Two of Power3 Medical Areas of Research

Breast Cancer

Power3’s early indication breast cancer NAF protein footprint test
More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer
NAF footprints for individualized therapy



Neurodegenerative Diseases - ALS (Lou Gehrig’s Disease), Alzheimer’s Disease, Parkinson’s Disease, Other Neurological Disorders

Power3’s blood serum test for distinguishing between the neurodegenerative diseases
Blood serum biomarkers and drug targets for neurodegenerative disease



Resistance to Chemotherapy

Power3’s test for prediction of response to drug therapy in cancer
Biomarkers and drug targets for treatment and monitoring of drug resistance





Continue your research at www.power3medical.com

______________________________________



Last: $2.99

LECG Corporation -  provides independent expert testimony and original authoritative studies in adversarial and non-adversarial environments to corporations and law firms, as well as local, state, and federal governments and agencies in the United States and internationally. The company conducts economic, financial, accounting, and statistical analyses to provide objective opinions and strategic advice to legislative, judicial, regulatory, and business decision makers.



XPRT recently announced it has signed a definitive agreement to acquire Bourne, a London-based independent business consultancy practice. Subject to customary conditions, the parties expect the closing of the acquisition to occur on July 2, 2010. This acquisition will add 36 people to LECG’s UK base, expanding LECG’s European presence to include specialists in valuation, transfer pricing, IP and tax consulting and advice as an extension to its finance, risk, process and operations services currently provided by its financial services practice. Bourne is a perfect fit for the new LECG as it seamlessly extends and enhances our disputes, valuation, IP and international tax practices.

“We are excited to add the credentials and experience of the Bourne team of professionals to LECG, fostering a true market-facing collaboration among our various business segments and geographic regions,” said Steve Samek, chief executive officer.

Keep track at http://www.lecg.com

_______________________________________



Last: $2.72

Intellipharmaceutics International Inc.  recently announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix(R) (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome. Sales of pantoprazole sodium delayed-release tablets in the United States were approximately $1.8 billion in 2009. Pantoprazole delayed-release tablets is the fourth ANDA product candidate that Intellipharmaceutics has disclosed from its 15 product pipeline, which includes both ANDA product candidates and the development of new drugs through the S.505(b)(2) New Drug Application (NDA) regulatory pathway.

Visit: http://www.intellipharmaceutics.com/



*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************



THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

*******************************************
End
Source:crwepicks
Email:***@crwepicks.com Email Verified
Tags:Biomedical, Ipci, Otc:pwrm, Pwrm, Pwrm Ob, Xprt
Industry:Stocks
Account Email Address Verified     Disclaimer     Report Abuse
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share